指南与共识多重用药老年慢病共病管理老年综合评估

老年心血管疾病患者药物治疗优化:多学科研讨会报告

Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop.
指南 / 共识 · J Am Geriatr Soc · 2018-12-07

该报告源自2017年美国国家老龄化研究所、美国心脏病学会和美国老年医学会联合举办的共识会议,旨在确定优化老年心血管疾病患者药物治疗的研究优先领域。会议指出需改善患者参与和沟通技能、整合多系统照护、弥补老年人群-efficacy试验数据缺乏、减少多重用药并提高依从性,并强调需开展传统与实用性研究以制定老年CVD循证指南。

要点

  • 优化老年CVD药物治疗需优先开展患者参与和沟通研究
  • 亟需整合多系统多学科照护以协调共病老年患者需求
  • 缺乏老年人群CVD药物疗效数据,需建立循证指南

核心结论

  • 老年CVD患者的需求与现行医疗系统设计不匹配,优化药物治疗需新研究数据以减少多重用药、提高依从性并实现以人为中心的目标。

研究设计与样本

  • 2017年2月6-7日由美国国家老龄化研究所、美国心脏病学会和美国老年医学会支持的共识会议,参与者包括心脏病学和老年医学领导者、政府机构代表、产业界及受训人员。

主要发现

  • 需改进患者参与和沟通技能以使医疗偏好与照护对齐。
  • 需整合系统和学科以协调共病老年患者的多提供者照护。
  • 缺乏与多数老年人相关的CVD药物疗效试验数据,导致治疗风险效益不确定。
  • 多重用药和用药不依从导致老年人不良结局,需研究适当处方和减处方。

临床怎么用

  • 临床应重视老年CVD患者的共同决策和沟通,整合多学科照护。
  • 应关注多重用药和依从性问题,探索减处方策略。
  • 需以患者为中心的目标指导药物治疗决策。

局限性

  • 本文为共识会议报告,未提供原始研究数据或定量分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify the top priority areas for research to optimize pharmacotherapy in older adults with cardiovascular disease (CVD). DESIGN: Consensus meeting. SETTING: Multidisciplinary workshop supported by the National Institute on Aging, the American College of Cardiology, and the American Geriatrics Society, February 6-7, 2017. PARTICIPANTS: Leaders in the Cardiology and Geriatrics communities, (officers in professional societies, journal editors, clinical trialists, Division chiefs), representatives from the NIA; National Heart, Lung, and Blood Institute; Food and Drug Administration; Centers for Medicare and Medicaid Services, Alliance for Academic Internal Medicine, Patient-Centered Outcomes Research Institute, Agency for Healthcare Research and Quality, pharmaceutical industry, and trainees and early career faculty with interests in geriatric cardiology. MEASUREMENTS: Summary of workshop proceedings and recommendations. RESULTS: To better align older adults' healthcare preferences with their care, research is needed to improve skills in patient engagement and communication. Similarly, to coordinate and meet the needs of older adults with multiple comorbidities encountering multiple healthcare providers and systems, systems and disciplines must be integrated. The lack of data from efficacy trials of CVD medications relevant to the majority of older adults creates uncertainty in determining the risks and benefits of many CVD therapies; thus, developing evidence-based guidelines for older adults with CVD is a top research priority. Polypharmacy and medication nonadherence lead to poor outcomes in older people, making research on appropriate prescribing and deprescribing to reduce polypharmacy and methods to improve adherence to beneficial therapies a priority. CONCLUSION: The needs and circumstances of older adults with CVD differ from those that the current medical system has been designed to meet. Optimizing pharmacotherapy in older adults will require new data from traditional and pragmatic research to determine optimal CVD therapy, reduce polypharmacy, increase adherence, and meet person-centered goals. Better integration of the multiple systems and disciplines involved in the care of older adults will be essential to implement and disseminate best practices. J Am Geriatr Soc 67:371-380, 2019.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Schwartz JB, Schmader KE, Hanlon JT, et al. Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop. J Am Geriatr Soc. 2018. PMID: 30536694. doi:10.1111/jgs.15634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。